Approach

Summary

Licensing status

Publication and contact information

Assays & screens

A refined, allele-specific quantitative PCR assay called Intplex for analysis of circulating cell-free DNA (cfDNA) mutations

Intplex could be used to characterize small, highly fragmented, tumor-derived cfDNA for diagnostic applications. Current cfDNA sequencing methods have difficulty determining the presence of point mutations in fragments smaller than 100 base pairs. In tumor tissue samples from patients with metastatic colorectal cancer, tumor tissue analysis methods detected K-Ras (KRAS) mutations in 36 of 95 samples and the BRAF V600E mutation in 5 of 95 samples. In plasma samples from the same patients, Intplex detected KRAS mutations in 37 of 95 samples and BRAF V600E mutations in 5 of 95 samples, giving a concordance of 96% and 100%. Ongoing work includes using Intplex to characterize samples from larger patient cohorts.

SciBX 7(15); doi:10.1038/scibx.2014.438
Published online April 17, 2014

Patented; exclusively licensed to an undisclosed company

Thierry, A.R. et al. Nat. Med.; published online March 23, 2014;
doi:10.1038/nm.3511
Contact: Alain R. Thierry, Montpellier Cancer Research Institute,
Montpellier, France
e-mail:

alain.thierry@inserm.fr